JP7292566B2 - 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 - Google Patents

子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 Download PDF

Info

Publication number
JP7292566B2
JP7292566B2 JP2019566909A JP2019566909A JP7292566B2 JP 7292566 B2 JP7292566 B2 JP 7292566B2 JP 2019566909 A JP2019566909 A JP 2019566909A JP 2019566909 A JP2019566909 A JP 2019566909A JP 7292566 B2 JP7292566 B2 JP 7292566B2
Authority
JP
Japan
Prior art keywords
weeks
day
patient
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019566909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522525A (ja
JP2020522525A5 (cg-RX-API-DMAC10.html
Inventor
ロウマイェ、アーネスト
ゴットランド、ジャン－ピエール
ポール、オリヴァー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of JP2020522525A publication Critical patent/JP2020522525A/ja
Publication of JP2020522525A5 publication Critical patent/JP2020522525A5/ja
Priority to JP2023043718A priority Critical patent/JP7485815B2/ja
Application granted granted Critical
Publication of JP7292566B2 publication Critical patent/JP7292566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2019566909A 2017-06-05 2018-06-05 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画 Active JP7292566B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023043718A JP7485815B2 (ja) 2017-06-05 2023-03-20 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515232P 2017-06-05 2017-06-05
US62/515,232 2017-06-05
PCT/EP2018/064767 WO2018224497A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023043718A Division JP7485815B2 (ja) 2017-06-05 2023-03-20 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画

Publications (3)

Publication Number Publication Date
JP2020522525A JP2020522525A (ja) 2020-07-30
JP2020522525A5 JP2020522525A5 (cg-RX-API-DMAC10.html) 2021-07-26
JP7292566B2 true JP7292566B2 (ja) 2023-06-19

Family

ID=62636157

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566909A Active JP7292566B2 (ja) 2017-06-05 2018-06-05 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画
JP2023043718A Active JP7485815B2 (ja) 2017-06-05 2023-03-20 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023043718A Active JP7485815B2 (ja) 2017-06-05 2023-03-20 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画

Country Status (18)

Country Link
US (2) US11759464B2 (cg-RX-API-DMAC10.html)
EP (2) EP4509173A3 (cg-RX-API-DMAC10.html)
JP (2) JP7292566B2 (cg-RX-API-DMAC10.html)
KR (1) KR102884301B1 (cg-RX-API-DMAC10.html)
CN (1) CN110996957A (cg-RX-API-DMAC10.html)
AU (2) AU2018280741B2 (cg-RX-API-DMAC10.html)
CA (1) CA3066188A1 (cg-RX-API-DMAC10.html)
DK (1) DK3634419T3 (cg-RX-API-DMAC10.html)
EA (1) EA201992812A1 (cg-RX-API-DMAC10.html)
ES (1) ES3018358T3 (cg-RX-API-DMAC10.html)
FI (1) FI3634419T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20250390T1 (cg-RX-API-DMAC10.html)
HU (1) HUE070907T2 (cg-RX-API-DMAC10.html)
MX (2) MX2019014482A (cg-RX-API-DMAC10.html)
PL (1) PL3634419T3 (cg-RX-API-DMAC10.html)
PT (1) PT3634419T (cg-RX-API-DMAC10.html)
SG (1) SG11201911599XA (cg-RX-API-DMAC10.html)
WO (1) WO2018224497A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223298A3 (en) 2013-03-15 2023-08-16 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
DK3634419T3 (da) 2017-06-05 2025-03-31 Kissei Pharmaceutical Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding
CA3107597A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
MA54058A (fr) 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
JP7459086B2 (ja) * 2018-11-07 2024-04-01 キッセイ薬品工業株式会社 エストロゲン依存性障害の治療のための組成物及び方法
EP4009976A1 (en) * 2019-08-08 2022-06-15 ObsEva S.A. Gnrh antagonists for the treatment of estrogen-dependent disorders
AU2020325655B2 (en) * 2019-08-08 2025-09-11 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of estrogen-dependent disorders
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525249A (ja) 2000-02-28 2003-08-26 プラエシス ファーマシューティカルズ インコーポレーテッド ＧｎＲＨアンタゴニストを用いてＦＳＨ関連状態を治療する方法
WO2011099507A1 (ja) 2010-02-10 2011-08-18 キッセイ薬品工業株式会社 縮合複素環誘導体の塩及びその結晶
JP2016513708A (ja) 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2418803C2 (ru) * 2005-10-19 2011-05-20 Киссеи Фармасьютикал Ко., Лтд. Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине
JP6268093B2 (ja) 2012-09-14 2018-01-24 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
BR112019002513A2 (pt) 2016-08-08 2019-05-14 Kissei Pharmaceutical Co., Ltd. uso e dosagem de agentes terapêuticos para endometriose
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
DK3634419T3 (da) 2017-06-05 2025-03-31 Kissei Pharmaceutical Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab
JP7459086B2 (ja) 2018-11-07 2024-04-01 キッセイ薬品工業株式会社 エストロゲン依存性障害の治療のための組成物及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525249A (ja) 2000-02-28 2003-08-26 プラエシス ファーマシューティカルズ インコーポレーテッド ＧｎＲＨアンタゴニストを用いてＦＳＨ関連状態を治療する方法
WO2011099507A1 (ja) 2010-02-10 2011-08-18 キッセイ薬品工業株式会社 縮合複素環誘導体の塩及びその結晶
JP2016513708A (ja) 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNUAL REPORT 2016，OBSEVA OBSTETRICS & BEYOND，2017年04月21日，Pages 1-48，http://obseva.across.health/wp-content/uploads/2019/07/ObsEva_AR_2016.pdf
Fertility and Sterility，2017年06月01日，Vol. 108, No. 1，Pages 152-160

Also Published As

Publication number Publication date
EP3634419B1 (en) 2025-01-29
AU2018280741A1 (en) 2020-01-30
MX2019014482A (es) 2020-08-17
AU2024201694A1 (en) 2024-04-04
JP2023078315A (ja) 2023-06-06
CN110996957A (zh) 2020-04-10
US11759464B2 (en) 2023-09-19
MX2023013582A (es) 2024-04-16
PT3634419T (pt) 2025-04-04
JP7485815B2 (ja) 2024-05-16
EP3634419A1 (en) 2020-04-15
ES3018358T3 (es) 2025-05-16
FI3634419T3 (fi) 2025-05-02
SG11201911599XA (en) 2020-01-30
EP4509173A2 (en) 2025-02-19
AU2018280741B2 (en) 2023-12-21
CA3066188A1 (en) 2018-12-13
KR102884301B1 (ko) 2025-11-11
WO2018224497A1 (en) 2018-12-13
EA201992812A1 (ru) 2020-05-21
US20240000785A1 (en) 2024-01-04
DK3634419T3 (da) 2025-03-31
HUE070907T2 (hu) 2025-07-28
US20200179390A1 (en) 2020-06-11
PL3634419T3 (pl) 2025-06-09
KR20200024797A (ko) 2020-03-09
EP4509173A3 (en) 2025-06-04
HRP20250390T1 (hr) 2025-05-23
JP2020522525A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
JP7485815B2 (ja) 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画
US20240293414A1 (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
WO2020094698A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
WO2021023877A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40116843A (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40027583B (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40027583A (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220613

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20230224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230320

R150 Certificate of patent or registration of utility model

Ref document number: 7292566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153